JPWO2020181034A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020181034A5 JPWO2020181034A5 JP2021552624A JP2021552624A JPWO2020181034A5 JP WO2020181034 A5 JPWO2020181034 A5 JP WO2020181034A5 JP 2021552624 A JP2021552624 A JP 2021552624A JP 2021552624 A JP2021552624 A JP 2021552624A JP WO2020181034 A5 JPWO2020181034 A5 JP WO2020181034A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- medicament
- jak1
- pathway inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025026650A JP2025087734A (ja) | 2019-03-05 | 2025-02-21 | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814085P | 2019-03-05 | 2019-03-05 | |
| US62/814,085 | 2019-03-05 | ||
| PCT/US2020/021088 WO2020181034A1 (en) | 2019-03-05 | 2020-03-05 | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025026650A Division JP2025087734A (ja) | 2019-03-05 | 2025-02-21 | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524997A JP2022524997A (ja) | 2022-05-11 |
| JP2022524997A5 JP2022524997A5 (https=) | 2023-03-13 |
| JPWO2020181034A5 true JPWO2020181034A5 (https=) | 2023-03-13 |
Family
ID=69941525
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552624A Pending JP2022524997A (ja) | 2019-03-05 | 2020-03-05 | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
| JP2025026650A Pending JP2025087734A (ja) | 2019-03-05 | 2025-02-21 | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025026650A Pending JP2025087734A (ja) | 2019-03-05 | 2025-02-21 | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11406640B2 (https=) |
| EP (2) | EP3934651A1 (https=) |
| JP (2) | JP2022524997A (https=) |
| KR (1) | KR20210137087A (https=) |
| CN (1) | CN114007621A (https=) |
| AU (1) | AU2020232757B2 (https=) |
| CA (1) | CA3132371A1 (https=) |
| EA (1) | EA202192426A1 (https=) |
| IL (1) | IL285999B2 (https=) |
| MA (1) | MA55201A (https=) |
| MX (2) | MX2021010545A (https=) |
| PH (1) | PH12021552130A1 (https=) |
| SG (1) | SG11202109563WA (https=) |
| UA (1) | UA130579C2 (https=) |
| WO (1) | WO2020181034A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3837258T (pt) | 2018-09-04 | 2024-06-20 | Theravance Biopharma R&D Ip Llc | Amidas de dimetil amino azetidina como inibidores de jak |
| WO2020051139A1 (en) | 2018-09-04 | 2020-03-12 | Theravance Biopharma R&D Ip, Llc | 5 to 7 membered heterocyclic amides as jak inhibitors |
| MX2021004582A (es) | 2018-10-29 | 2021-06-15 | Theravance Biopharma R&D Ip Llc | Compuesto 2-azabiciclo hexano inhibidor de jak. |
| CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| MA55201A (fr) * | 2019-03-05 | 2022-01-12 | Incyte Corp | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| EP4274578A1 (en) * | 2021-01-11 | 2023-11-15 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
| TW202317550A (zh) | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| KR102952944B1 (ko) | 2021-10-15 | 2026-04-14 | 주식회사 엘지에너지솔루션 | 용접봉 체결 방법 및 이에 의해 용접봉이 수직으로 체결된 용접 장치 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE273695T1 (de) | 2000-06-28 | 2004-09-15 | Smithkline Beecham Plc | Nassvermahlung |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| US20070219223A1 (en) | 2006-03-07 | 2007-09-20 | Endacea, Inc. | Compositions and methods for treating respiratory disorders |
| US8058227B2 (en) | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| EP2684564A1 (en) | 2008-04-17 | 2014-01-15 | Sanofi | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation |
| JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体 |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| PE20121336A1 (es) | 2009-12-01 | 2012-11-03 | Abbvie Inc | Nuevos compuestos triciclicos |
| PT3354652T (pt) | 2010-03-10 | 2020-07-20 | Incyte Holdings Corp | Derivados de piperidin-4-ilazetidina como inibidores de jak1 |
| RU2013120966A (ru) | 2010-10-08 | 2014-11-20 | Эббви Инк. | ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| AU2013274030B2 (en) | 2012-06-15 | 2016-07-07 | Sun Pharmaceutical Industries, Inc. | Deuterated derivatives of ruxolitinib |
| CA2880083A1 (en) | 2012-08-17 | 2014-02-20 | Concert Pharmaceuticals, Inc. | Deuterated baricitinib |
| CN104918945B (zh) | 2012-11-01 | 2018-01-05 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
| WO2014138168A1 (en) | 2013-03-06 | 2014-09-12 | Incyte Corporation | Processes and intermediates for making a jak inhibitor |
| SMT201900223T1 (it) | 2013-05-17 | 2019-07-11 | Incyte Corp | Sale di bipirazolo come inibitore di jak |
| SG10201801069QA (en) * | 2013-08-07 | 2018-03-28 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| EP3060234A1 (en) * | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
| JP6576941B2 (ja) * | 2014-02-28 | 2019-09-18 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | 骨髄異形成症候群の治療のためのｊａｋ１阻害剤 |
| CN106687462A (zh) | 2014-04-30 | 2017-05-17 | 因赛特公司 | Jak1抑制剂的制备方法以及其新形式 |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| HK1252685A1 (zh) | 2015-11-03 | 2019-05-31 | Theravance Biopharma R&D Ip, Llc | 用於治疗呼吸疾病的jak激酶抑制剂化合物 |
| CN105294699B (zh) * | 2015-12-04 | 2019-06-11 | 上海勋和医药科技有限公司 | 巴瑞替尼的制备方法 |
| KR102399848B1 (ko) * | 2016-10-03 | 2022-05-19 | 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 | 신규한 jak1 선택적 억제제 및 그 용도 |
| EP3327020A1 (en) * | 2016-11-29 | 2018-05-30 | Sandoz Ag | Citrate salts of a janus kinase (jak) inhibitor |
| BR112019018648A2 (pt) | 2017-03-09 | 2020-06-16 | Theravance Biopharma R&D Ip, Llc | Inibidores de jak contendo uma amida heterocíclica com 4 membros |
| US10406148B2 (en) | 2017-05-01 | 2019-09-10 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| EA202091830A1 (ru) | 2018-01-30 | 2020-12-29 | Инсайт Корпорейшн | Способы и промежуточные соединения для получения ингибитора jak |
| IL311485B1 (en) | 2018-02-16 | 2026-01-01 | Incyte Corp | JAK1 pathway inhibitors for the treatment of cytokine-related disorders |
| MD3773593T2 (ro) | 2018-03-30 | 2024-10-31 | Incyte Corp | Tratament hidradenitei supurative utilizând inhibitori ai JAK |
| CA3097025A1 (en) | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| CA3123596A1 (en) | 2018-12-19 | 2020-06-25 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
| MA55201A (fr) | 2019-03-05 | 2022-01-12 | Incyte Corp | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
-
2020
- 2020-03-05 MA MA055201A patent/MA55201A/fr unknown
- 2020-03-05 UA UAA202105585A patent/UA130579C2/uk unknown
- 2020-03-05 AU AU2020232757A patent/AU2020232757B2/en active Active
- 2020-03-05 EA EA202192426A patent/EA202192426A1/ru unknown
- 2020-03-05 WO PCT/US2020/021088 patent/WO2020181034A1/en not_active Ceased
- 2020-03-05 JP JP2021552624A patent/JP2022524997A/ja active Pending
- 2020-03-05 SG SG11202109563WA patent/SG11202109563WA/en unknown
- 2020-03-05 EP EP20713496.6A patent/EP3934651A1/en active Pending
- 2020-03-05 CN CN202080024215.0A patent/CN114007621A/zh active Pending
- 2020-03-05 CA CA3132371A patent/CA3132371A1/en active Pending
- 2020-03-05 MX MX2021010545A patent/MX2021010545A/es unknown
- 2020-03-05 US US16/810,045 patent/US11406640B2/en active Active
- 2020-03-05 KR KR1020217031644A patent/KR20210137087A/ko active Pending
- 2020-03-05 PH PH1/2021/552130A patent/PH12021552130A1/en unknown
- 2020-03-05 IL IL285999A patent/IL285999B2/en unknown
- 2020-03-05 EP EP25213638.7A patent/EP4691567A3/en active Pending
-
2021
- 2021-09-02 MX MX2024007081A patent/MX2024007081A/es unknown
-
2022
- 2022-06-30 US US17/854,443 patent/US11896595B2/en active Active
-
2025
- 2025-02-21 JP JP2025026650A patent/JP2025087734A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Opolski et al. | Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study | |
| JPWO2020181034A5 (https=) | ||
| US11896595B2 (en) | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction | |
| EP1350511B1 (en) | Medicinal compositions containing aspirin | |
| Rosenzweig et al. | Extracorporeal life support bridge for pulmonary hypertension: a high-volume single-center experience | |
| Dhariwal et al. | Sildenafil in pediatric pulmonary arterial hypertension | |
| JP2008540486A (ja) | Ｐｄｅ４インヒビター及びテトラヒドロビオプテリン誘導体との組合せ物 | |
| CO6251256A2 (es) | Sales del inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4il)1h-pirazol-1-il)-3-ciclopentilpropanitrilo | |
| AU2013237503A1 (en) | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease | |
| IL310203A (en) | Pharmaceutical composition containing 2-{4n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide | |
| ZA200707930B (en) | Roflumilast for the treatment of pulmonary hypertension | |
| CN102149377A (zh) | 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途 | |
| JP7620758B2 (ja) | 肺動脈性肺高血圧症の治療方法 | |
| JPWO2020132210A5 (https=) | ||
| JP2013528649A5 (https=) | ||
| Nagaya | Drug therapy of primary pulmonary hypertension | |
| JP2002255814A (ja) | アスピリンを含有する医薬組成物 | |
| BR112015010969B1 (pt) | Uso de um composto (r)-5-(2-(benzilamino)etil)-1-(6,8-difluorcroman-3-il)-1h-imidazol-2(3h)-tiona | |
| CA2629339A1 (en) | Pyrazolo[4,3-d]pyrimidin-5-yl) derivative used as pde5 inhibitors | |
| Rabbani et al. | The role of magnesium therapy in acute myocardial infarction | |
| KR20130101447A (ko) | 크산틴 옥시다아제 억제제 및 안지오텐신 ⅱ 수용체 길항제 및 이의 용도 | |
| KR20250010046A (ko) | IL-6 및/또는 IL-1β 억제제 | |
| Brown et al. | Effect of early treatment with propranolol on left ventricular function four weeks after myocardial infarction. | |
| JPWO2022150676A5 (https=) | ||
| Cosgrove et al. | The use of three factor prothrombin complex concentrate to reverse warfarin treated mechanical circulatory device patients immediately prior to heart transplant |